Sol-Gel Technologies Shares Outstanding 2016-2018 | SLGL

Sol-Gel Technologies shares outstanding history from 2016 to 2018. Shares outstanding can be defined as the number of shares held by shareholders (including insiders) assuming conversion of all convertible debt, securities, warrants and options. This metric excludes the company's treasury shares.
  • Sol-Gel Technologies shares outstanding for the quarter ending June 30, 2018 were 0.019B, a 201.27% increase year-over-year.
  • Sol-Gel Technologies 2017 shares outstanding were 0.006B, a 0% decline from 2016.
  • Sol-Gel Technologies 2016 shares outstanding were 0.006B, a 0% decline from 2015.
  • Sol-Gel Technologies 2015 shares outstanding were 0.006B, a INF% increase from .
Sol-Gel Technologies Annual Shares Outstanding
(Millions of Shares)
2017 6
2016 6
2015 6
Sol-Gel Technologies Quarterly Shares Outstanding
(Millions of Shares)
Q2 2018 19
Q1 2018 15
Q4 2017 0
Q3 2017 0
Q2 2017 6
Q4 2016 0
Q4 2015 0
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $0.125B $0.000B
Sol-Gel Technologies a clinical-stage dermatology company. It focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. Its product candidates include VERED for the treatment of papulopustular rosacea, TWIN and SIRS-T for the treatment of acne vulgaris, which are in its clinical stage. Sol-Gel Technologies based in Israel.
Stock Name Country Market Cap PE Ratio
Allergan (AGN) Ireland $64.335B 11.04
Teva Pharmaceutical Industries (TEVA) Israel $21.792B 6.09
Mylan (MYL) United Kingdom $16.606B 7.06
Bausch Health Cos (BHC) Canada $8.483B 6.32
Dr Reddy's Laboratories (RDY) India $5.756B 25.71
Supernus Pharmaceuticals (SUPN) United States $2.517B 26.93
Mallinckrodt Public (MNK) United Kingdom $2.287B 3.89
Akorn (AKRX) United States $0.882B 0.00
Amphastar Pharmaceuticals (AMPH) United States $0.857B 123.53
Homology Medicines (FIXX) United States $0.747B 0.00
CymaBay Therapeutics (CBAY) United States $0.615B 0.00
Assembly Biosciences (ASMB) United States $0.594B 0.00
Voyager Therapeutics (VYGR) United States $0.498B 0.00
Adamas Pharmaceuticals (ADMS) United States $0.485B 0.00
Progenics Pharmaceuticals (PGNX) United States $0.482B 0.00
Corium (CORI) United States $0.454B 0.00
Teligent (TLGT) United States $0.185B 0.00
Zynerba Pharmaceuticals (ZYNE) United States $0.120B 0.00
Aevi Genomic Medicine (GNMX) United States $0.074B 0.00
Aquinox Pharmaceuticals (AQXP) Canada $0.061B 0.00
Evoke Pharma (EVOK) United States $0.044B 0.00
Acasti Pharma (ACST) Canada $0.037B 0.00
Versartis (ARAV) United States $0.037B 0.00
Agile Therapeutics (AGRX) United States $0.033B 0.00
Pernix Therapeutics Holdings (PTX) United States $0.010B 0.00